193 related articles for article (PubMed ID: 23997116)
1. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J; Yang C; Kireev D; Simpson C; Norris-Drouin J; Hull-Ryde EA; Janzen WP; Johnson GL; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2013 Nov; 12(11):2367-77. PubMed ID: 23997116
[TBL] [Abstract][Full Text] [Related]
2. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q; Liu J; Zhang D; DeRyckere D; Wang X; Frye S; Earp HS; Graham DK
Oncotarget; 2015 Mar; 6(9):6722-36. PubMed ID: 25762638
[TBL] [Abstract][Full Text] [Related]
4. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
Linger RM; Lee-Sherick AB; DeRyckere D; Cohen RA; Jacobsen KM; McGranahan A; Brandão LN; Winges A; Sawczyn KK; Liang X; Keating AK; Tan AC; Earp HS; Graham DK
Blood; 2013 Aug; 122(9):1599-609. PubMed ID: 23861246
[TBL] [Abstract][Full Text] [Related]
5. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
Linger RM; DeRyckere D; Brandão L; Sawczyn KK; Jacobsen KM; Liang X; Keating AK; Graham DK
Blood; 2009 Sep; 114(13):2678-87. PubMed ID: 19643988
[TBL] [Abstract][Full Text] [Related]
6. Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.
Koda Y; Itoh M; Tohda S
Anticancer Res; 2018 Jan; 38(1):199-204. PubMed ID: 29277773
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C; Keating AK; Earp HS; Liang X; DeRyckere D; Graham DK
Oncogene; 2013 Nov; 32(46):5359-68. PubMed ID: 23474756
[TBL] [Abstract][Full Text] [Related]
8. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target.
Weingart MF; Roth JJ; Hutt-Cabezas M; Busse TM; Kaur H; Price A; Maynard R; Rubens J; Taylor I; Mao XG; Xu J; Kuwahara Y; Allen SJ; Erdreich-Epstein A; Weissman BE; Orr BA; Eberhart CG; Biegel JA; Raabe EH
Oncotarget; 2015 Feb; 6(5):3165-77. PubMed ID: 25638158
[TBL] [Abstract][Full Text] [Related]
9. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.
Bernsmeier C; Pop OT; Singanayagam A; Triantafyllou E; Patel VC; Weston CJ; Curbishley S; Sadiq F; Vergis N; Khamri W; Bernal W; Auzinger G; Heneghan M; Ma Y; Jassem W; Heaton ND; Adams DH; Quaglia A; Thursz MR; Wendon J; Antoniades CG
Gastroenterology; 2015 Mar; 148(3):603-615.e14. PubMed ID: 25479139
[TBL] [Abstract][Full Text] [Related]
10. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
Cummings CT; Linger RM; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
Oncotarget; 2014 Nov; 5(21):10434-45. PubMed ID: 25372020
[TBL] [Abstract][Full Text] [Related]
11. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
12. UNC1062, a new and potent Mer inhibitor.
Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C; Norris-Drouin J; Sather S; Kireev D; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
Eur J Med Chem; 2013 Jul; 65():83-93. PubMed ID: 23693152
[TBL] [Abstract][Full Text] [Related]
13. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
Zhang W; Zhang D; Stashko MA; DeRyckere D; Hunter D; Kireev D; Miley MJ; Cummings C; Lee M; Norris-Drouin J; Stewart WM; Sather S; Zhou Y; Kirkpatrick G; Machius M; Janzen WP; Earp HS; Graham DK; Frye SV; Wang X
J Med Chem; 2013 Dec; 56(23):9683-92. PubMed ID: 24195762
[TBL] [Abstract][Full Text] [Related]
14. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
15. UNC569-induced Morphological Changes in Pigment Epithelia and Photoreceptor Cells in the Retina through MerTK Inhibition in Mice.
Sayama A; Okado K; Nakamura K; Kawaguchi T; Iguchi T; Makino T; Yabe K; Kai K; Mori K
Toxicol Pathol; 2018 Feb; 46(2):193-201. PubMed ID: 29310530
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
20. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]